retatrutide diabetes trial Eli Lilly just announced striking Phase 3 results for retatrutide, an experimental “triple agonist” that acts on three gut-hormone targets at once. On the top dose, people lost an average of 28% Retatrutide FDA Approval Status 2026:
Description
This is especially important during higher-volume or higher-intensity phases

The SURMOUNT program (obesity) added thousands more, including the head-to-head SURMOUNT-5 trial against semaglutide

Based on the number of stimulation electrodes, GES can be classified into single-channel GES and multichannel GES

Ozempic exclusively targets GLP-1 receptors

Leavens, PhD , can be reached at [email protected].
